Features & Functions
SARS-CoV-2 Protein Interactome
SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA beta coronavirus belonging to the order of nidovirales. In the first three months since its initial identification in December 2019 SARS-CoV-2 has caused more than 800.000 confirmed cases and over 40.000 fatalities worldwide of the associated severe acute respiratory syndrome COVID-19 (coronavirus disease 2019) .
Presently, no vaccine is available to curb the virus’ spread. A potential source for COVID-19 therapeutics are existing antiviral reagents that are either already approved or in development for the treatment of the other two respiratory syndromes – SARS and MERS – caused by human coronaviruses (hCoVs)2,3. A deeper understanding of the function of the virus and its proteins is essential for the targeted application of existing drugs and the discovery of new ones [4,5,6.]
The 30kb SARS-CoV-2 genome encodes 16 non-structural proteins (Nsp1-16), four structural proteins (spike, envelope, nucleocapsid, membrane), and nine putative accessory factors . Many of these proteins and polypeptides have a number or interaction partners in particular in lung cells, the virus’ primary infection site. These interactions with the host cell determine the virus’ ability to infect the cell, reproduce its genome and trigger the production and release of new virus particles. In addition, several virus proteins appear to have interaction partners affecting innate immune pathways such as the interferon signaling pathway, NF-kappa B inflammatory response, type I interferon production, and IRF-3 activation.
Some of these regulatory functions are shared with other pathogenic human viruses. Therefore, a deeper understanding of these mechanisms may lead to the identification of targets and development of novel therapeutics relevant for future virus pandemics.
1. Dong, Ensheng; Du, Hongru; Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. (2020).
2. Morse, J. S., Lalonde, T., Xu, S. & Liu, W. R. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. Chembiochem 21, 730–738 (2020).
3. Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149–150 (2020).
4. Báez-Santos, Y. M., St. John, S. E. & Mesecar, A. D. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21–38 (2015).
5. Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342 (2019).
6. Coutard, B. et al. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 176, 104742 (2020).
7. David E. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Matthew J. O’Meara, Jeffrey Z. Guo, Danielle L. Swaney, Tia A. Tummino, Ruth Huettenhain, Robyn M. Kaake, Alicia L. Richards, Beril Tutuncuoglu, Helene Foussard, Jyoti Batra, N. J. K. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential DrugRepurposing. (2020).
The COVID -19 Virus Kit is intended for in vitro diagnostic use.
The COVID-19 IgM Ab Rapid Test is used to detect the Novel Corona Virus-19 IgM Antibody in serum / plasma / whole blood qualitatively.
It is based on the principle of immunochromatographic test and uses capture method to detect the COVID-19 IgM antibody in the sample.
COVID-19, it is a novel coronavirus with new strain that has not been previously identified in humans,
belongs to Coronaviruses (CoV) such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV).
Comparative Test Report
SARS-CoV-2 IgM Ab Rapid Test
In this trial, 1300 clinical samples were selected. There were 300 positive samples and 1000 negative samples.
The SARS-CoV-2 IgM Ab rapid test and the SARS-CoV-2 PCR test were detected simultaneously, and the positive coincidence rate, negative coincidence rate, and total coincidence rate were calculated.
（1）300 cases of positive samples confirmed by Nucleic Acid Test: tested with SARS-CoV-2 IgM Ab rapid test, 246 cases were positive, 54 cases were negative.
（2）1000 cases of negative samples confirmed by Nucleic Acid Test: tested with SARS-CoV-2 IgM Ab rapid test, 960 cases were negative, 40 cases were positive.
（1）Results statistics table
2）Analysis of coincidence rate of SARS-CoV-2 IgM Ab rapid test and PCR test in serum samples
Positive coincidence rate=246/（246+54）×100%=82%
Negative coincidence rate=960/（40+960）×100%=96%
Total coincidence rate=（246+960）/（246+54+40+960）×100%=92.8%
SARS-CoV-2 IgM Ab rapid test and PCR test positive coincidence rate of 82%, negative coincidence rate of 96%, total coincidence rate of 92.8%.
Comparative Test Report
SARS-CoV-2 IgG Ab Rapid Test
In this trial, 1300 clinical samples were selected. There were 300 positive samples and 1000negative samples.
The SARS-CoV-2 IgG Ab rapid test and the SARS-CoV-2 PCR were detected simultaneously, and the positive coincidence rate, negative coincidence rate, and total coincidence rate were calculated.
（1）300 cases of positive samples confirmed by PCR Test: tested with SARS-CoV-2 IgG Ab rapid test, 279 cases were positive, 21 cases were negative.
（2）1000 cases of negative samples confirmed by PCR Test: tested with SARS-CoV-2 IgG Ab rapid test, 975 cases were negative, 25 cases were positive.
（1）Results statistics table
（2）Analysis of coincidence rate of SARS-CoV-2 IgG Ab rapid test and PCR test in serum samples
Positive coincidence rate=279/（279+21）×100%=93%
Negative coincidence rate=975/（25+975）×100%=97.5%
Total coincidence rate=（279+975）/（279+21+25+975）×100%=96.5%
SARS-CoV-2 IgG Ab rapid test and PCR test positive coincidence rate of 93%, negative coincidence rate of 97.5%, total coincidence rate of 96.5%.
Do you have further questions for us?
Basel Office (HQ)
Basel Grosspeter Tower
CH-4052 Basel, Switzerland
T +41 (0) 61 564 12 34
Christoph Merian-Ring 11
CH-4153 Reinach, Switzerland
T +41 (0) 61 271 70 70
F +41 (0) 61 271 70 71
Copyright 2012 © Swissavans AG. All rights reserved.